Distinct Transcriptional MYCN/c-MYC Activities Are Associated with Spontaneous Regression or Malignant Progression in Neuroblastomas

Overview

Journal Genome Biol

Specialties Biology
Genetics

Date 2008 Oct 15

PMID 18851746

Citations 122

Authors

Frank Westermann

Daniel Muth

Axel Benner

Tobias Bauer

Kai-Oliver Henrich

Andre Oberthuer

Benedikt Brors

Tim Beissbarth

Jo Vandesompele

Filip Pattyn

Barbara Hero

Rainer Konig

Matthias Fischer

Manfred Schwab

Affiliations

Soon will be listed here.

Abstract

Background: Amplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20% of neuroblastomas and identifies a highly aggressive subtype. In MYCN single-copy neuroblastomas, elevated MYCN mRNA and protein levels are paradoxically associated with a more favorable clinical phenotype, including disseminated tumors that subsequently regress spontaneously (stage 4s-non-amplified). In this study, we asked whether distinct transcriptional MYCN or c-MYC activities are associated with specific neuroblastoma phenotypes.

Results: We defined a core set of direct MYCN/c-MYC target genes by applying gene expression profiling and chromatin immunoprecipitation (ChIP, ChIP-chip) in neuroblastoma cells that allow conditional regulation of MYCN and c-MYC. Their transcript levels were analyzed in 251 primary neuroblastomas. Compared to localized-non-amplified neuroblastomas, MYCN/c-MYC target gene expression gradually increases from stage 4s-non-amplified through stage 4-non-amplified to MYCN amplified tumors. This was associated with MYCN activation in stage 4s-non-amplified and predominantly c-MYC activation in stage 4-non-amplified tumors. A defined set of MYCN/c-MYC target genes was induced in stage 4-non-amplified but not in stage 4s-non-amplified neuroblastomas. In line with this, high expression of a subset of MYCN/c-MYC target genes identifies a patient subtype with poor overall survival independent of the established risk markers amplified MYCN, disease stage, and age at diagnosis.

Conclusions: High MYCN/c-MYC target gene expression is a hallmark of malignant neuroblastoma progression, which is predominantly driven by c-MYC in stage 4-non-amplified tumors. In contrast, moderate MYCN function gain in stage 4s-non-amplified tumors induces only a restricted set of target genes that is still compatible with spontaneous regression.

Citing Articles

Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities.

Jiang Z, Allkanjari M, Chung P, Tran H, Ghanbari-Azarnier R, Wang D Cancers (Basel). 2025; 17(5).

PMID: 40075567 PMC: 11898778. DOI: 10.3390/cancers17050720.

Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.

Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .

PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.

A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway.

Froney M, Cook C, Cadiz A, Flinter K, Ledeboer S, Chan B ACS Pharmacol Transl Sci. 2024; 7(9):2799-2819.

PMID: 39296266 PMC: 11406699. DOI: 10.1021/acsptsci.4c00251.

Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity.

Aljouda N, Shrestha D, DeVaux C, Olsen R, Alleboina S, Walker M Mol Oncol. 2024; 19(3):808-824.

PMID: 39119816 PMC: 11887674. DOI: 10.1002/1878-0261.13714.

A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.

Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schroder C Commun Biol. 2024; 7(1):919.

PMID: 39079981 PMC: 11289481. DOI: 10.1038/s42003-024-06596-6.

References

Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S . MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006; 5(9):2358-65. DOI: 10.1158/1535-7163.MCT-06-0305. View

Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R . Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene. 2007; 27(10):1478-88. DOI: 10.1038/sj.onc.1210769. View

Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R . Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006; 24(31):5070-8. DOI: 10.1200/JCO.2006.06.1879. View

OGeen H, Nicolet C, Blahnik K, Green R, Farnham P . Comparison of sample preparation methods for ChIP-chip assays. Biotechniques. 2006; 41(5):577-80. PMC: 2268903. DOI: 10.2144/000112268. View

Cohn S, London W, Huang D, Katzenstein H, Salwen H, Reinhart T . MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000; 18(21):3604-13. DOI: 10.1200/JCO.2000.18.21.3604. View

Boon K, Caron H, van Asperen R, Valentijn L, Hermus M, van Sluis P . N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001; 20(6):1383-93. PMC: 145518. DOI: 10.1093/emboj/20.6.1383. View

Ambros P, Ambros I . Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol. 2001; 37(6):492-504. DOI: 10.1002/mpo.1242. View

Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M . Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002; 18 Suppl 1:S96-104. DOI: 10.1093/bioinformatics/18.suppl_1.s96. View

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A . The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111(2):241-50. DOI: 10.1016/s0092-8674(02)01014-0. View

10.

Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N . ArrayExpress--a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 2003; 31(1):68-71. PMC: 165538. DOI: 10.1093/nar/gkg091. View

11.

Wiedemeyer R, Westermann F, Wittke I, Nowock J, Schwab M . Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene. 2003; 22(3):401-11. DOI: 10.1038/sj.onc.1206150. View

12.

Strieder V, Lutz W . E2F proteins regulate MYCN expression in neuroblastomas. J Biol Chem. 2002; 278(5):2983-9. DOI: 10.1074/jbc.M207596200. View

13.

Schilling F, Spix C, Berthold F, Erttmann R, Sander J, Treuner J . Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer Lett. 2003; 197(1-2):19-28. DOI: 10.1016/s0304-3835(03)00077-6. View

14.

Schwab M, Westermann F, Hero B, Berthold F . Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003; 4(8):472-80. DOI: 10.1016/s1470-2045(03)01166-5. View

15.

Zeller K, Jegga A, Aronow B, ODonnell K, Dang C . An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003; 4(10):R69. PMC: 328458. DOI: 10.1186/gb-2003-4-10-r69. View

16.

Edsjo A, Nilsson H, Vandesompele J, Karlsson J, Pattyn F, Culp L . Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest. 2004; 84(4):406-17. DOI: 10.1038/labinvest.3700061. View

17.

Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, Mori T . Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet. 1984; 2(8397):271-3. DOI: 10.1016/s0140-6736(84)90311-8. View

18.

Schwab M, Varmus H, Bishop J . Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature. 1985; 316(6024):160-2. DOI: 10.1038/316160a0. View

19.

Seeger R, Brodeur G, Sather H, Dalton A, Siegel S, Wong K . Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111-6. DOI: 10.1056/NEJM198510313131802. View

20.

Sadee W, Yu V, Richards M, Preis P, Schwab M, Brodsky F . Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. Cancer Res. 1987; 47(19):5207-12. View